Immix Biopharma Inc. Company Profile
NASDAQ: IMMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:21 PM ET
Immix Biopharma at a glance
Immix Biopharma Inc. (NASDAQ: IMMX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Los Angeles, CA. Immix Biopharma is led by Dr. Ilya Rachman M.B.A., M.D., Ph.D. and employs about 21 people. The company's shares have traded publicly since 2021.
At a market capitalization of $799.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001873835, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Immix Biopharma do?
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Business description based on the company's public filings.
Company information
- Legal name
- Immix Biopharma Inc.
- Ticker
- NASDAQ: IMMX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ilya Rachman M.B.A., M.D., Ph.D.
- Employees
- 21
- Headquarters
- 11400 West Olympic Boulevard, Los Angeles, CA, United States
- Phone
- 310 651 8041
- Website
- immixbio.com
- IPO year
- 2021
- Market cap
- $799.18M
- SEC CIK
- 0001873835
Companies similar to Immix Biopharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVBPArriVent BioPharma Inc. | 16.27 | -3.67% | $802.24M | vs IMMX |
| IVAInventiva S.A. American Depository Shares | 3.35 | -0.45% | $791.34M | vs IMMX |
| GERNGeron Corporation | 1.20 | +0.01% | $771.03M | vs IMMX |
| OBXObsidian Therapeutics Inc. | 12.46 | -5.64% | $769.38M | vs IMMX |
| ARDXArdelyx Inc. | 3.22 | -1.23% | $831.36M | vs IMMX |
| HELPHelus Pharma Inc. | 10.45 | -0.57% | $763.48M | vs IMMX |
| APMDApnimed Inc. | 18.23 | +1.05% | $758.93M | vs IMMX |
| LXRXLexicon Pharmaceuticals Inc. | 1.71 | -3.13% | $758.65M | vs IMMX |